Procaps Group

About Us

Procaps Group, S.A. ("Procaps Group") (NASDAQ: PROC) is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,300 collaborators working under a sustainable model. Procaps develops, manufactures, and markets over the counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.

ESG Report 2021

Committed to Innovation for a Healthier World

Read more
ESG Report

Press Realease

Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024

MIAMI & BARRANQUILLA, Colombia --(BUSINESS WIRE)--Nov. 22, 2023-- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today a strategic leadership transition as Ruben Minski, founder and CEO of Procaps prepares to transition

November 22, 2023 

Read more - ENG

Read more - ESP

Read more - PT

Pharmaceutical Group
dedicated to delivering
health and nutrition

We employ over 5,500 people across 13 countries

Our products reach 
50+ markets